Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | SAT1 | P21673 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701914 | 1.00 | HTT (0.34) | HTTSAT1SMN1; SMN2CA2CA1 | |
| SCHEMBL576070 | 0.79 | SMN1; SMN2 (0.36) | HTTSMN1; SMN2CA2CA1CA9 | |
| SCHEMBL1978140 | 0.79 | FBP1 (0.38) | HTTSMN1; SMN2CA2CA1CA9 | |
| SCHEMBL2154913 | 0.79 | HTT (0.37) | HTTSMN1; SMN2CA2CA1CA9 | |
| SCHEMBL575164 | 0.79 | SMN1; SMN2 (0.36) | HTTSMN1; SMN2CA2CA1CA9 | |
| SCHEMBL6840461 | 0.77 | SAT1 (0.35) | SAT1CA2FDPS | |
| Hydrochloric Acid SCHEMBL11040547 | 0.77 | HTT (0.36) | HTTSMN1; SMN2CA2CA1CA9 | |
| SCHEMBL19712632 | 0.77 | HTT (0.36) | HTTSMN1; SMN2CA2CA1CA9 | |
| SCHEMBL2700146 | 0.77 | HTT (0.36) | HTTSMN1; SMN2CA2CA1CA9 | |
| SCHEMBL28206224 | 0.77 | FBP1 (0.37) | HTTSMN1; SMN2CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9579332-B2 | Phosphonate analogs of HIV inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9457035-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20140288294-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20130090299-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20080076740-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | GILEAD SCIENCES, INC. | 2007-12-06 | — | — | US | disclosed |
| US-7300924-B2 | Anti-infective phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070078081-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070072809-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027114-A1 | Phosphonate analogs of antimetabolites | GILEAD SCIENCES INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027116-A1 | Therapeutic phosphonate derivatives | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072809-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | HTT 2190/4885SAT1 4310/4885SMN1; SMN2 3000/4885 |
| US-20070027116-A1 | Therapeutic phosphonate derivatives | PPP5C, PPP3CA, PPP4R3A | HTT 4171/4885SAT1 2528/4885SMN1; SMN2 4765/4885 |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | HTT 2981/4885SAT1 2624/4885SMN1; SMN2 1380/4885 |
| US-20130090299-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | HTT 3923/4885SAT1 3904/4885SMN1; SMN2 4228/4885 |
| US-20070078081-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | HTT 2414/4885SAT1 4303/4885SMN1; SMN2 3253/4885 |
| US-20070027114-A1 | Phosphonate analogs of antimetabolites | TYMP, PHOSPHO1, PHPT1 | HTT 3061/4885SAT1 2849/4885SMN1; SMN2 3512/4885 |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | HTT 3435/4885SAT1 2354/4885SMN1; SMN2 1554/4885 |
| US-20180086784-A1 | Phosphonate analogs of HIV inhibitor compounds | PIK3CA, TYMP, ITPA | HTT 3923/4885SAT1 3904/4885SMN1; SMN2 4228/4885 |
| US-20170210770-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | PIK3CA, TYMP, ITPA | HTT 3923/4885SAT1 3904/4885SMN1; SMN2 4228/4885 |
| US-20140288294-A1 | ANTIVIRAL COMPOUNDS | EIF2AK2, MAVS, ITPA | HTT 2589/4885SAT1 4508/4885SMN1; SMN2 2390/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | HTT 3435/4885SAT1 2354/4885SMN1; SMN2 1554/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | HTT 3441/4885SAT1 2695/4885SMN1; SMN2 3324/4885 |
| US-20080076740-A1 | Antiviral compounds | EIF2AK2, MAVS, ITPA | HTT 2589/4885SAT1 4508/4885SMN1; SMN2 2390/4885 |
| US-20070281907-A1 | Kinase Inhibitor Phosphonate Conjugates | PIK3CA, PNKP, PLK1 | HTT 3838/4885SAT1 2774/4885SMN1; SMN2 3706/4885 |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | PNP, TYMP, MTAP | HTT 3573/4885SAT1 2158/4885SMN1; SMN2 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.